{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-21-000052","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.655285+00:00","generated_at":"2026-06-28T10:48:25.129255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Net loss $17.4M in Q3; cash $290.2M; SL-172154/SL-279252 Phase 1 data; Takeda deal terminated","bullets":["Net loss $17.4M ($0.41/share) vs $11.8M ($1.54/share) in Q3 2020; cash $290.2M, down from $335.4M.","SL-172154 Phase 1 in ovarian cancer well-tolerated with high CD47 occupancy; dose escalation continues to 10mg/kg.","SL-279252 Phase 1 in solid tumors: one confirmed partial response, stable disease in 12 of 43 patients.","Shattuck and Takeda mutually terminated collaboration; Shattuck regains full rights to SL-279252 and SL-115154.","Cash runway sufficient into H2 2024; guidance reduced due to increased SL-172154 clinical and manufacturing costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-21-000052","json":"https://secwatch.observer/filing/0001680367-21-000052.json","markdown":"https://secwatch.observer/filing/0001680367-21-000052.md","text":"https://secwatch.observer/filing/0001680367-21-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036721000052/0001680367-21-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036721000052/sttk-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:48:25.129255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}